Yttrium-90 Radioembolization of Hepatocellular Carcinoma–Performance Technical Advances and Future Concepts

摘要

Hepatocellular carcinoma (HCC) is a lethal tumor, claiming over half a million lives per year. Treatment of HCC is commonly performed without curative intent, and palliative options dominate, including catheter-based therapies, namely, transarterial chemoembolization and yttrium-90 (⁹⁰Y) radioembolization. This review will showcase the performance of ⁹⁰Y radioembolization for the treatment of HCC, focusing on recent seminal data and technical advances. In particular, novel radioembolization treatment concepts are discussed and compared with conventional HCC therapy.